Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 24, 2014
Pharmacy Choice - Pharmaceutical News - Research results from Catholic University of Korea, Department of Internal Medicine update knowledge of systemic lupus erythematosus risk factors - October 24, 2014

Pharmacy News Article

 4/6/10 - Research results from Catholic University of Korea, Department of Internal Medicine update knowledge of systemic lupus erythematosus risk factors

Scientists discuss in 'Incidence of cancer among female patients with systemic lupus erythematosus in Korea' new findings in systemic lupus erythematosus. According to a study from Seoul, South Korea, "This study aims to ascertain the incidence of cancer in patients with systemic lupus erythematosus (SLE) in comparison with that in the general population in Korea, and to identify the cancer-types, the organ involvement, and the association with immunosuppressive therapy. The study subjects were consecutive SLE patients evaluated at Kangnam St."

"Mary's hospital between 1997 and 2007. The incidence rate of cancer was calculated and was analyzed in comparison to that of age-and sex-matched cohort obtained from the Korea National Cancer Registry. Nine hundred fourteen patients were observed for a total of 5,716 person-years. A total of 16 cases of cancer occurred. The average age at the diagnosis of cancer and the mean disease duration were 43 years and 11 years, respectively. The standardized incidence ratio (SIR) of all cancers was 1.45 (95% CI 0.74-2.16); The SIRs for the three most frequent cancers were 3.42 for cervix cancer (CI 0.00-7.26), 15.37 for non-Hodgkin's lymphoma (NHL; CI 2.90-37.68), and 43.55 for bladder cancer (CI 8.21-106.78). There were significant differences in the hematologic and renal involvement between SLE patients with cancer and without. Cyclophosphamide therapy, especially with cumulative dose more than 6 g (p=0.017), seemed to contribute to the increased risk of cancer. Long disease duration, damage, and hematologic involvement were associated with increased risk of cancer occurrence. SLE patients are at high risk for NHL and bladder cancer," wrote K.Y. Kang and colleagues, Catholic University of Korea, Department of Internal Medicine (see also Systemic Lupus Erythematosus Risk Factors).

The researchers concluded: "Active cancer screening is required in SLE patients with long disease duration and damage who are treated with high dose cyclophosphamide."

Kang and colleagues published the results of their research in Clinical Rheumatology (Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clinical Rheumatology, 2010;29(4):381-8).

For additional information, contact K.Y. Kang, St. Mary's Hospital, The Catholic University of Korea, Dept. of Internal Medicine, The Catholic University of Korea, Seoul, South Korea.

The publisher of the journal Clinical Rheumatology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA.



(c) 2010 Cancer Weekly via NewsRx.com

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Oct 26: Clinical Decision Support & Mobile Applications: Tools That Help Pharmacies Be Successful
Oct 28: Update on the Treatment for Major Depressive Disorder
Oct 29: Florida Medication Error Reduction
Oct 30: Atrial Fibrillation Treatment in Older Adults
Oct 31: How Low Can You Go: Glucose Monitoring in Type 2 Diabetes
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415